Hagino Hiroshi
School of Health Science, Faculty of Medicine, Tottori University, Japan.
Clin Calcium. 2014 Mar;24(3):339-47.
The goals of osteoporosis treatment are prevention of fracture. If the patients with higher risk of fragility fractures are treated, the larger effect on reduction of the risk of fragility fractures is expected. Criteria for initiating pharmacological treatment in U.S.A or Europe are based on cost-effectiveness. In Japan, the criteria for initiating pharmacological treatment to prevent fragility fracture were established in the revised version of 2011 guidelines for prevention and treatment of osteoporosis. In these criteria, postmenopausal women and men age 50 and older with vertebral fracture are considered for treatment regardless of bone density. FRAX® was newly introduced to consider whether or not to initiate pharmacological treatment in persons without a fragility fracture who have a low bone mass.
骨质疏松症治疗的目标是预防骨折。如果对脆性骨折风险较高的患者进行治疗,预期对降低脆性骨折风险的效果会更大。美国或欧洲启动药物治疗的标准基于成本效益。在日本,2011年骨质疏松症防治指南修订版中确立了启动预防脆性骨折药物治疗的标准。在这些标准中,无论骨密度如何,绝经后女性和50岁及以上有椎体骨折的男性都被考虑进行治疗。新引入了FRAX®来考虑是否对骨量低但无脆性骨折的人启动药物治疗。